Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Enovis (ENOV)

Enovis Q3 sales rise 9% to $549 million; net loss of $571 million on $548 million impairment

Mixed Impact 4 of 5 earnings Written later

Enovis reported third-quarter 2025 net sales of $549 million, up 9% on a reported basis and 7% organically, and raised its full-year adjusted EBITDA and adjusted EPS guidance. The GAAP net loss of $571 million, or $9.99 per share, reflects a non-cash goodwill impairment charge of $548 million, which the company says does not affect future operations.

Key points

  • Q3 adjusted EBITDA was $95 million (17.3% of sales), compared with $90 million (17.9%) a year earlier; adjusted EPS was $0.75 versus $0.73.
  • Full-year 2025 adjusted EBITDA guidance rose to $395-405 million from $392-402 million; adjusted EPS guidance rose to $3.10-3.25 from $3.05-3.20.
  • Full-year revenue guidance is $2.24-2.27 billion, versus prior $2.245-2.275 billion, including a $15 million reduction tied to the Dr. Comfort divestiture completed in October 2025.
  • In October 2025, Enovis divested its Diabetic Footcare business unit from Prevention & Recovery for total proceeds of up to $60 million.

The filing

CompanyEnovis (ENOV)
Form8-K, current report
Filed with the SECNov 6, 2025, 6:09 AM ET
Accession number0001420800-25-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.